Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jul 27, 2015 at 8:21 AM EDT

Short Sellers Run For Cover From Major Pharma

ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a…

Chris Lange | Jul 27, 2015 at 7:57 AM EDT

Short Sellers Back Off Major Biotechs

ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of…

Douglas A. McIntyre | Jul 27, 2015 at 4:44 AM EDT

Teva Will Buy Allergan Generics for $40.5 Billion

In a deal which had been anticipated, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would buy Allergan Generics in a…

Jon C. Ogg | Jul 26, 2015 at 10:21 AM EDT

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings…

Jon C. Ogg | Jul 24, 2015 at 9:45 AM EDT

Is This the End of Sunesis?

Sunesis Pharmaceuticals probably wishes that this Friday never happened, as shares were down almost 70% just after the opening bell.

Chris Lange | Jul 24, 2015 at 9:10 AM EDT

Are AbbVie Earnings Enough?

AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.

Paul Ausick | Jul 24, 2015 at 8:25 AM EDT

Why Biogen Shares Are Tumbling After Earnings Report

Biogen reported mixed second-quarter 2015 results before markets opened Friday morning.

Chris Lange | Jul 23, 2015 at 1:55 PM EDT

What to Look for in Biogen Earnings Report

Biogen is scheduled to release its second-quarter financial results before the markets open on Friday.

Jon C. Ogg | Jul 23, 2015 at 1:45 PM EDT

Can Cara Ultimately Get Its Drug Approved?

Cara Therapeutics may not be a household name, but its shares scream higher on Thursday after clearing Phase 2 trial…

Chris Lange | Jul 23, 2015 at 1:25 PM EDT

What to Expect From AbbVie Earnings

Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.

Chris Lange | Jul 23, 2015 at 11:05 AM EDT

How Much New Eli Lilly Product Launches Boosted the Bottom Line

Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.

Chris Lange | Jul 23, 2015 at 10:55 AM EDT

Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress

Bristol-Myers Squibb released better-than-expected second-quarter financial results before the markets opened Thursday.

Chris Lange | Jul 23, 2015 at 9:50 AM EDT

Celgene Earnings Beat and Updated Guidance

Celgene released better-than-expected second-quarter earnings report Thursday before the markets opened.

Chris Lange | Jul 22, 2015 at 2:00 PM EDT

Illumina Gets a Reset

Illumina reported mixed second-quarter financial results on Wednesday before the markets opened.

Jon C. Ogg | Jul 22, 2015 at 1:55 PM EDT

Biogen Faces Mixed Alzheimer’s Reception

It seems Biogen's closely watched Alzheimer's drug candidate, aducanumab, has fallen short of analyst and investor expectations.

1 … 254 255 256 257 258 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Run For Cover From Major Pharma

Short Sellers Back Off Major Biotechs

Teva Will Buy Allergan Generics for $40.5 Billion

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Is This the End of Sunesis?

Are AbbVie Earnings Enough?

Why Biogen Shares Are Tumbling After Earnings Report

What to Look for in Biogen Earnings Report

Can Cara Ultimately Get Its Drug Approved?

What to Expect From AbbVie Earnings

How Much New Eli Lilly Product Launches Boosted the Bottom Line

Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress

Celgene Earnings Beat and Updated Guidance

Illumina Gets a Reset

Biogen Faces Mixed Alzheimer’s Reception

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Run For Cover From Major Pharma

Short Sellers Back Off Major Biotechs

Teva Will Buy Allergan Generics for $40.5 Billion

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Is This the End of Sunesis?

Are AbbVie Earnings Enough?

Why Biogen Shares Are Tumbling After Earnings Report

What to Look for in Biogen Earnings Report

Can Cara Ultimately Get Its Drug Approved?

What to Expect From AbbVie Earnings

How Much New Eli Lilly Product Launches Boosted the Bottom Line

Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress

Celgene Earnings Beat and Updated Guidance

Illumina Gets a Reset

Biogen Faces Mixed Alzheimer’s Reception

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how